Core Viewpoint - The investment logic of "mother holding child" is gaining attention among fund managers as they seek undervalued stocks in the Hong Kong market, particularly in the pharmaceutical sector [1][3]. Group 1: Market Trends - Following a significant surge in the stock of Boan Biotechnology, a subsidiary of Green Leaf Pharmaceutical, which rose by 66%, another subsidiary, HeartTech Medical, saw a 47% increase, indicating a trend of "smoking stocks" in the Hong Kong pharmaceutical sector [2][3]. - The influx of new capital into the Hong Kong market is evident as public funds are shifting their focus from U.S. medical device stocks to A-share and Hong Kong pharmaceutical assets [2][5]. Group 2: Fund Manager Strategies - Fund managers are increasingly adopting a strategy of directly holding shares in parent companies rather than their subsidiaries, reflecting a preference for companies with stronger business fundamentals and competitive advantages [3][4]. - A notable shift in a QDII fund's portfolio was observed, where the allocation to A-shares and Hong Kong stocks increased significantly, indicating a strategic pivot away from U.S. stocks [6]. Group 3: Industry Performance - HeartTech Medical reported a total revenue of 472 million yuan, a year-on-year increase of 44.4%, and a net profit of 246 million yuan, up 62.22%, showcasing strong performance in the sector [4]. - The pharmaceutical sector is expected to show relative gains by 2025, driven by new industry trends and a recovery from historically low valuation levels [8][9]. Group 4: Policy and Innovation - Recent favorable policies for the pharmaceutical industry, including support for drug and medical device innovation, are expected to enhance the growth prospects for innovative drug companies [9]. - The increasing global presence of Chinese innovative drug companies is highlighted by their significant contributions to international academic conferences, indicating a robust growth trajectory [9].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 心未来 2025 年 4 月 19 日， 乐普医疗 （ 300003.SZ ）公布其 2024 年及 2025 年第一季度 的财务报告 。 尽管整体在 2024 年面临业绩下滑的挑战，但在 2025 年第一季度部分业务已开始复苏 ，尤其是 结 构性心脏病业务 和 冠脉植介入业务 等板块表现突出。公司正在积极调整业务结构，优化收入来源， 未来有望逐步恢复增长态势。 # 财报数据 2024 年整体业绩下滑， 2025Q1 部分业务复苏 2024 年全年 2025 年 Q1 公司实现收入 17.36 亿元，同比下降 9.67% ；归母净利润 3.79 亿元，同比下降 21.44% ；扣非归母 净利润 3.37 亿元，同比下降 26.08% 。 尽管整体业绩仍处于下滑态势，但部分业务板块已出现积极变化。 业务板块拆分：结构性心脏病业务增长强劲 2024 年全年 医疗器械板块收入 33.26 亿元 ，同比 下降 9.47% 。 其中， 冠脉植介入业务 收入 16.22 亿元 ， 同比增长 6.35% ...

分行业来看，2024年，其医疗器械板块实现营业收入33.26亿元，同比下降9.47%；药品板块实现营业收入17.58亿元，同比下降42.25%；医疗服务及健康管 理板块实现营业收入10.19亿元，同比下降19.24%。 | | | | 毛利率 | 营业收入 | 营业成本 | | --- | --- | --- | --- | --- | --- | | | 营业收入 | 营业成本 | | 比上年同 | 比上年同 | | | | | | 期增减 | 期增减 | | 分行业 | | | | | | | 医疗器械 | 3, 326, 491, 257. 02 | 1, 011, 376, 771. 63 | 69. 60% | -9. 47% | -17. 38% | | 药品 | 1, 757, 747, 768. 26 | 813, 026, 692. 22 | 53.75% | -42. 25% | -14. 68% | | 医疗服务及健康管理 | 1, 019, 030, 080. 60 | 563, 243, 637. 78 | 44. 73% | -19. 24% | -16. 72% | 值得注意的是 ...

Core Viewpoint - Lepu Medical is experiencing a significant decline in performance, marking the end of its growth phase, with 2024 showing a substantial drop in revenue and profit compared to previous years [1][3]. Financial Performance - In 2022, Lepu Medical achieved revenue of 10.609 billion yuan, with a net profit of 2.246 billion yuan, reflecting a year-on-year growth of 26.15% [1]. - For 2024, the company reported revenue of 6.103 billion yuan, a decrease of 23.52%, and a net profit of 247 million yuan, down 80.37% year-on-year, marking the lowest since its IPO [1][2]. - The first quarter of 2025 also showed a decline, with revenue of 1.736 billion yuan, down 9.67%, and net profit of 379 million yuan, down 21.44% [2]. Asset Impairment and Business Challenges - Lepu Medical faced significant asset impairment losses totaling 251 million yuan in 2024, which heavily impacted its net profit [3]. - The company reported a decline across all major business segments in 2024: medical devices revenue fell by 9.47%, pharmaceuticals by 42.25%, and healthcare services by 19.24% [4]. Market Environment and Competition - The company is grappling with increased market competition, particularly in the cardiovascular device sector, where it faces strong rivals like MicroPort and Boston Scientific [5]. - The normalization of volume-based procurement has negatively affected the pricing and sales of Lepu Medical's products, leading to a significant drop in revenue from its core generic drugs [6][7]. Strategic Focus for Recovery - Lepu Medical aims to pivot towards innovation, consumer healthcare, and international expansion as key strategies for recovery [8][9]. - The company has developed a range of innovative products in the cardiovascular space and is actively pursuing new drug development, including a candidate for obesity and type II diabetes [10]. - The focus on consumer healthcare includes entering markets such as ophthalmology and dermatology, with several products in the registration phase [11]. Conclusion - Despite current challenges, Lepu Medical's foundational strengths and market demand in the cardiovascular sector provide a basis for potential recovery, contingent on effective execution of its strategic initiatives [8].

证券代码：300003 证券简称：乐普医疗 乐普（北京）医疗器械股份有限公司 投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 | | --- | --- | | 投资者关系活 | □新闻发布会 □路演活动 | | 动类别 | | | | □现场参观 | | | □其他 | | 参与单位名称 | | | | 108 家境内外机构共 154 名参会人员，详见附件明细 | | 及人员姓名 | | | 时间 | 2025 年 4 月 20 日 | | 地点 | 电话会议 | | 上市公司接待 | 董事长 蒲忠杰 | | | 财务总监 王泳 | | 人员姓名 | 董事会秘书 江维娜 | | | 公司介绍： | | | 各位投资者上午好，感谢大家来参加业绩说明会，我先介绍一 | | | 下公司 2024 年业绩情况和 2025 年展望。 | | | 2024 年公司总体营收同比下降 23.52%，其中医疗器械板块营收 | | | 同比下降 9.47%，主要是因为体外诊断业务降幅较大，冠脉植介入 | | | 和结构性心脏病业务分别同比增长 6.35%和 44.0 ...

Core Viewpoint - Lepu Medical reported a significant decline in financial performance for the year 2024, with a notable drop in revenue and net profit compared to the previous year [1][2]. Financial Performance Summary - The company's operating revenue for 2024 was 6.10 billion yuan, a decrease of 23.52% from 2023's 7.98 billion yuan [2]. - Net profit attributable to shareholders was 246.94 million yuan, down 80.37% from 1.26 billion yuan in 2023 [2]. - The net profit after deducting non-recurring gains and losses was 221.43 million yuan, reflecting an 80.28% decline from 1.12 billion yuan in the previous year [2]. - The net cash flow from operating activities was 734.64 million yuan, a decrease of 25.82% compared to 990.36 million yuan in 2023 [2]. Historical Comparison - In 2023, Lepu Medical's operating revenue was 7.98 billion yuan, down 24.78% from 2022 [3]. - The net profit attributable to shareholders in 2023 was 1.26 billion yuan, a decrease of 42.91% from 2022 [3]. - The net cash flow from operating activities in 2023 was 990.36 million yuan, down 64.51% from 2022 [3]. Profit Distribution Plan - The company approved a profit distribution plan, proposing a cash dividend of 1.35 yuan per 10 shares (including tax) to all shareholders, with no bonus shares [2].

乐普医疗 20250420 摘要 Q&A 公司在 2024 年和 2025 年一季度的财务表现如何？ 2024 年公司的整体营收下降，主要原因是诊断板块的收入减少。器械板块的营 收下降了 9%，其中心血管板块仍保持增长，增幅约为 10%。药品板块的降幅最 大，约为 40%，其中原料药降幅约 20%，制剂药品降幅约 42%。服务和医疗板块 也受到新冠疫情影响显著下降。总体来看，公司 2024 年的销售额降低了 20%， • 乐普医疗 2024 年销售额下降 20%，利润下降 80%，主要受原料药、制剂药 品及疫情影响，但 2025 年一季度收入和利润已明显回暖。公司通过裁员 1,600 人（含 400 研发人员）、优化营销策略、关闭亏损业务等措施应对 挑战。 • 公司预计 2025 年经营状况好转，药品销售额预计同比增长 30%左右，器械 增长 10%左右，主要来自心血管、外科及诊断领域。中美贸易脱钩可能带 来进口替代机会，利好公司发展。 • 公司现金流稳定，2023 年净现金流 9-10 亿元，2024 年 7 亿元。分红和股 票回购显示公司信心。对美国出口业务影响有限，但中美脱钩加速进口替 代，为起搏器等领 ...

证券研究报告 乐普医疗 (300003 CH) 1Q25 业绩环比改善，看好 25 年发展向上 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 20 日│中国内地 | 医疗器械 | 结构性心脏病业务表现亮眼，看好公司三大板块 25 年发展向上 1）器械：24 年/1Q25 收入 33.26/9.04 亿元（yoy-9.5%/+2.1%），其中结构 性心脏病业务在多款新品获批背景下表现亮眼， 24 年 /1Q25 收入 yoy+44.0%/+37.4%；看好板块收入25年重回稳健增长。2）药品：24年/1Q25 收入 17.58/5.95 亿元（yoy-42.3%/-25.0%），主因行业政策影响下终端进货 意愿降低，但目前零售渠道库存已基本清理完毕，1Q25 板块收入已边际明 显改善（qoq+111.4%），看好板块收入 25 年恢复稳健增长；3）医疗服务 及健康管理：24 年/1Q25 收入 10.19/2.38 亿元（yoy-19.2%/-2.4%），主因 板块发展策略调整；看好板块 25 年伴随新品上市实现向好发展。 产品矩阵 ...

公司体外诊断业务产品线齐全，覆盖生化、免疫（化学发光）、分子、血液与凝血、POCT 等体外诊断各细分领域和 重要技术平台。报告期内，体外诊断业务实现营业收入3.33亿元，同比下降51.31%，主要原因是部分产品竞争加剧价 格回落，公司人员和战略调整使业务产生一定波动，目前人员优化已告一段落，预计业务将逐步恢复正常增长。 药品板块实现营业收入17.58亿元，同比下降 42.25%。其中，制剂（仿制药）实现营业收入14.09亿元，同比下降 46.50%；原料药实现营业收入3.49亿元，同比下降 14.99%。公司制剂业务在核心产品纳入国家集采后，主动调整销售 策略，将重心转向 OTC 零售端。 近日，乐普医疗发布2024年财报。披露公司去年营收下滑23.52%至61.03亿元，归属净利下滑80.37%至2.47亿元。 医疗器械板块是公司业务中收入规模最大的板块，细分业务板块主要包括心血管植介入、体外诊断、外科麻醉三大板 块，其中心血管植介入是公司核心业务板块。报告期内，该板块实现营业收入33.26亿元，同比下降9.47%。心血管植 介入：冠脉植介入业务实现营业收入16.22亿元，同比增长6.35%，结构性心脏病业 ...

—— 2024 年年报及 2025 年一季报业绩点评 维持 程培 孟熙 | 市场数据 | 2025-04-18 | | --- | --- | | 股票代码 | 300003.SZ | | A 股收盘价(元) | 10.87 | | 上证指数 | 3276.73 | | 总股本(万股) | 188061.11 | | 实际流通 A 股(万股) | 161609.84 | | 流通 A 股市值(亿元) | 175.67 | ⚫ ⚫ ⚫ ⚫ · 医药行业 ⚫⚫ 公司点评报告 · 医药行业 E券|CGS 附录: 公司财务预测表 | 资产负债表(百万元) | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 流动资产 | 8436.28 | 10340.26 | 11453.76 | 12768.24 | | 现金 | 3718.02 | 5383.28 | 6291.37 | 7448.06 | | 应收账款 | 1530.66 | 1639.89 | 1720.60 | 1795.56 | | 其它应收款 | 114.40 | 12 ...